Researchers at Priavoid GmbH, Heinrich Heine University Düsseldorf, and Forschungszentrum Jülich have demonstrated that an optimized all-D-peptide, designated SVD-17 (also known as PRI-101), targets monomeric alpha-synuclein to inhibit de novo aggregation, dismantle pre-existing aggregates, and extend median survival in a seeded mouse model of Parkinson’s disease by approximately 14%.
Parkinson’s disease is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons. The pathology centers on the accumulation of aggregates of alpha-synuclein, an intrinsically disordered protein that is physiologically present predominantly in its soluble monomeric form. Under pathological conditions, these monomers assemble into oligomers and larger aggregates that accumulate as intracellular deposits and can act as seeds to promote further aggregation, contributing to neuronal dysfunction and neurodegeneration.
Experimental Compound Stops Protein Aggregates from Growing
- Targeting the Building Blocks: Instead of trying to break apart stubborn protein clumps after they have already formed, this experimental compound binds directly to the individual, loose protein molecules—called monomers—shifting the aggregation equilibrium toward the monomeric state to stop aggregates from growing.
- Brain Penetration: Following daily subcutaneous dosing in preclinical testing, the peptide successfully reached the central nervous system, with a reported half-life of approximately 50 to 80 hours.
- Survival Benefit: In mice engineered to model synucleinopathy, continuous administration of the peptide starting one week after fibril challenge extended median survival from 272 days in the placebo group to 310 days.
Biophysical Disassembly and Preclinical Efficacy of SVD-17
Previous efforts to develop disease-modifying therapies targeting alpha-synuclein have mainly focused on recognizing and removing pathological assemblies. The research consortium pursued an alternative strategy. By utilizing an all-D-peptide—constructed exclusively from D-amino acids rather than L-amino acids—the compound gains high resistance to proteolytic degradation, making it potentially well suited for therapeutic applications.
α-Synuclein Aggregate-Disassembling Compounds Prolong Survival in a Mouse Model of Parkinson's Diseasehttps://t.co/nnW5CcEzeR pic.twitter.com/I12Bdanw1i
Biophysical evaluations using dynamic light scattering revealed that SVD-17 reduces the particle size of pre-formed alpha-synuclein aggregates in a concentration-dependent manner. In an alpha-syn-overexpressing cell model, the compound reduced intracellular aggregate formation and reduced cellular toxicity. Pharmacokinetic profiling in mice demonstrated that daily subcutaneous dosing achieved a brain concentration of approximately 140 nanomolars (nM) 24 hours after the final dose, confirming prolonged central nervous system persistence.
| Treatment Group (Mouse Model) | Dosing Regimen | Median Survival | Survival Extension vs. Placebo |
|---|---|---|---|
| Placebo Controls | Continuous Osmotic Minipump | 272.0 Days | Baseline |
| SVD-17 Treatment | 10 mg/kg/day for 12 Weeks | 310.0 Days | ~14% Increase |
| SVD-1a Treatment | Continuous Osmotic Minipump | 313.5 Days | Not stated |
Comparative Evaluation of Peptide Analogues in Synucleinopathy Models
The study evaluated SVD-17 alongside its first-generation compound, SVD-1a, which was detailed in earlier findings published under DOI: 10.1038/s41531-025-01132-7. Hemizygous TgM83+/− mice, which express human alpha-synuclein carrying the familial A53T mutation, were subjected to experimental seeding with pre-formed alpha-syn aggregates to develop synucleinopathy.
Treatment commenced one week after fibril challenge, when the pathological process had already been initiated. Continuous delivery via subcutaneous osmotic minipumps at 10 mg/kg/day for 12 weeks yielded survival benefits. While SVD-17 extended median survival to 310 days, the related compound SVD-1a resulted in a median survival of 313.5 days. By contrast, the increase observed with the parent compound, SVD-1, was not statistically significant.
Preclinical Status Precludes Human Dosing Guidelines
Because SVD-17 (PRI-101) remains in the preclinical phase of pharmaceutical development, no clinical contraindications or approved human dosing guidelines exist. Patients diagnosed with Parkinson’s disease or related synucleinopathies should not attempt to source or self-administer investigational peptides. Anyone experiencing new or worsening motor symptoms must consult a qualified neurologist or movement disorder specialist to discuss standard-of-care management options.
Whether this all-D-peptide mechanism will successfully translate into disease modification for human patients remains to be established as Priavoid advances PRI-101 toward clinical development.
References
- ChemistryViews. All-D-Peptide Disassembles α-Synuclein Aggregates in Parkinson’s Disease.
- SVD-1a preclinical identification data. DOI: 10.1038/s41531-025-01132-7.
